Lupin launches first generic version of Oracea in United States

10 Apr 2024 Evaluate

Lupin has launched first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (USFDA). Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline Capsules had estimated annual sales of $128 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

1653.00 15.45 (0.94%)
30-Apr-2024 10:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1517.65
Dr. Reddys Lab 6279.75
Cipla 1409.75
Zydus Lifesciences 956.85
Lupin 1653.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.